tiprankstipranks
Advertisement
Advertisement

TCRX Stock Latest News

TScan Therapeutics Expands Authorized Shares After Stockholder Vote
Company AnnouncementsTScan Therapeutics Expands Authorized Shares After Stockholder Vote
2d ago
8K
TCRX
Buy Rating Reiterated on TSC-101 Ahead of Key ALLOHA Readouts and Pipeline Expansion; $6 Price Target Maintained
PremiumRatings
Buy Rating Reiterated on TSC-101 Ahead of Key ALLOHA Readouts and Pipeline Expansion; $6 Price Target Maintained
18d ago
TCRX
TScan Therapeutics reports Q1 EPS (22c), consensus (17c)
PremiumThe Fly
TScan Therapeutics reports Q1 EPS (22c), consensus (17c)
18d ago
TCRX
TScan Therapeutics Consolidates Finance Leadership After Officer Resignation
PremiumCompany Announcements
TScan Therapeutics Consolidates Finance Leadership After Officer Resignation
2M ago
8K
TCRX
Buy 2 ‘Strong Buy’ Biotech Stocks With 400%+ Upside, According to Wall Street
PremiumMarket News
Buy 2 ‘Strong Buy’ Biotech Stocks With 400%+ Upside, According to Wall Street
3M ago
CRVO
TCRX
TScan Therapeutics price target raised to $5 from $4 at Wedbush
PremiumThe FlyTScan Therapeutics price target raised to $5 from $4 at Wedbush
3M ago
TCRX
TScan Therapeutics: Strengthening Heme-Focused TCR-T Platform and Regulatory Momentum Support Buy Rating and $7 Target
Premium
Ratings
TScan Therapeutics: Strengthening Heme-Focused TCR-T Platform and Regulatory Momentum Support Buy Rating and $7 Target
3M ago
TCRX
TScan Therapeutics reports Q4 EPS (18c), consensus (28c)
Premium
The Fly
TScan Therapeutics reports Q4 EPS (18c), consensus (28c)
3M ago
TCRX
TScan Therapeutics sees cash runway into 2H27
PremiumThe Fly
TScan Therapeutics sees cash runway into 2H27
3M ago
TCRX
TScan Therapeutics: Clinical Momentum in TSC-101 and Pipeline Expansion Underpin Buy Rating Despite Cash Constraints
PremiumRatings
TScan Therapeutics: Clinical Momentum in TSC-101 and Pipeline Expansion Underpin Buy Rating Despite Cash Constraints
3M ago
TCRX
TScan Therapeutics completes enrollment into Cohort C of ALLOHA study
PremiumThe Fly
TScan Therapeutics completes enrollment into Cohort C of ALLOHA study
3M ago
TCRX
TScan Therapeutics Outlines Pivotal 2026 Outlook in Presentation
PremiumCompany Announcements
TScan Therapeutics Outlines Pivotal 2026 Outlook in Presentation
4M ago
8K
TCRX
Hold Rating for TScan Therapeutics Amid Promising Data and Awaited Future Developments
PremiumRatingsHold Rating for TScan Therapeutics Amid Promising Data and Awaited Future Developments
6M ago
TCRX
TScan Therapeutics: Overcoming Manufacturing Setbacks with Strategic Adjustments and Promising Potential in Myeloid Malignancies
Premium
Ratings
TScan Therapeutics: Overcoming Manufacturing Setbacks with Strategic Adjustments and Promising Potential in Myeloid Malignancies
6M ago
TCRX
Promising Potential of TScan Therapeutics’ TSC-101: Analyst Recommends Buy Rating
Premium
Ratings
Promising Potential of TScan Therapeutics’ TSC-101: Analyst Recommends Buy Rating
6M ago
TCRX
TScan Therapeutics announces updated data from ALLOHA Phase 1 trial
PremiumThe Fly
TScan Therapeutics announces updated data from ALLOHA Phase 1 trial
6M ago
TCRX
TScan Therapeutics Approves Key Employee Retention Program
PremiumCompany Announcements
TScan Therapeutics Approves Key Employee Retention Program
6M ago
8K
TCRX
TScan Therapeutics downgraded to Equal Weight from Overweight at Morgan Stanley
PremiumThe Fly
TScan Therapeutics downgraded to Equal Weight from Overweight at Morgan Stanley
6M ago
TCRX
TScan Therapeutics Reports Increased Revenue Amid Rising Losses
PremiumCompany Announcements
TScan Therapeutics Reports Increased Revenue Amid Rising Losses
6M ago
TCRX
TScan Therapeutics: Strategic Focus and Financial Stability Drive Buy Rating
PremiumRatingsTScan Therapeutics: Strategic Focus and Financial Stability Drive Buy Rating
6M ago
TCRX
Promising Phase I Results and Strategic Adjustments Support Buy Rating for TScan Therapeutics
Premium
Ratings
Promising Phase I Results and Strategic Adjustments Support Buy Rating for TScan Therapeutics
6M ago
TCRX
TScan Therapeutics reports Q3 EPS (28c), consensus (33c)
Premium
The Fly
TScan Therapeutics reports Q3 EPS (28c), consensus (33c)
6M ago
TCRX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >